Ziprasidone has 22 known drug interactions based on U.S. FDA drug labeling data. Of these, 3 are contraindicated combinations that should be avoided entirely. 7 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Drugs That Prolong Qtc Interval, Macimorelin Acetate, Pimozide. Patients taking Ziprasidone should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 22
- Contraindicated
- 3
- Major
- 7
- Moderate
- 8
- Minor
- 1
Contraindicated (3)
- Ziprasidone + Drugs That Prolong Qtc Interval— Ziprasidone should not be used in combination with other drugs that have demonstrated QT prolongation due to risk of ser…
- Ziprasidone + Macimorelin Acetate— Co-administration may lead to torsade de pointes-type ventricular tachycardia due to QT prolongation. Avoid concomitant …
- Ziprasidone + Pimozide— Additive QT interval prolongation effect anticipated, increasing risk of ventricular arrhythmias.
Major (7)
- Ziprasidone + Amphetamine— Risk of serotonin syndrome with concomitant therapy with amphetamines.
- Ziprasidone + Buspirone— Risk of serotonin syndrome with concomitant therapy with buspirone.
- Ziprasidone + Lithium— Risk of serotonin syndrome with concomitant therapy with lithium.
- Ziprasidone + St. John'S Wort— Risk of serotonin syndrome with concomitant therapy with St. John's Wort.
- Ziprasidone + Tetrabenazine— Antipsychotic that prolongs QTc interval and increases risk for Parkinsonism, NMS, and akathisia when used concomitantly…
- Ziprasidone + Triptans— Risk of serotonin syndrome with concomitant therapy with triptans.
- Ziprasidone + Tryptophan— Risk of serotonin syndrome with concomitant therapy with tryptophan.
Moderate (8)
- Ziprasidone + Acidifying Agents— Ziprasidone may enhance the effects of antihypertensive agents due to its potential for inducing hypotension.
- Ziprasidone + Carbamazepine— Carbamazepine induces CYP3A4, decreasing ziprasidone AUC by approximately 35%, potentially reducing ziprasidone efficacy…
- Ziprasidone + Centrally Acting Drugs— Caution should be used when ziprasidone is taken with other centrally acting drugs due to primary CNS effects of ziprasi…
- Ziprasidone + Dopamine Agonists— Ziprasidone may antagonize the effects of dopamine agonists.
- Ziprasidone + Haloperidol Decanoate— Drug known to prolong QTc interval; caution advised when used with haloperidol decanoate due to risk of QT prolongation.
- Ziprasidone + Haloperidol Lactate— Drug known to prolong QTc interval; caution advised when used with haloperidol due to risk of QT prolongation.
- Ziprasidone + Ketoconazole— Ketoconazole, a potent CYP3A4 inhibitor, increases ziprasidone AUC and Cmax by approximately 35-40%.
- Ziprasidone + Levodopa— Ziprasidone may antagonize the effects of levodopa.
Minor (1)
- Ziprasidone + Cimetidine— Cimetidine at 800 mg daily for 2 days did not affect ziprasidone pharmacokinetics.